mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease

Alexis R. Demonbreun*, Matthew P. Velez, Rana Saber, Daniel T. Ryan, Amelia Sancilio, Thomas W. McDade, Elizabeth M. McNally

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

SARS-CoV-2 vaccines protect against symptomatic and severe COVID-19. The BNT162b2/Pfizer and mRNA-1273/Moderna vaccines represent new vaccine technology relying on administration of mRNA encoding SARS-CoV-2 viral spike protein encased in lipid nanoparticles. The vaccines are administered as two doses into muscle, which elicits a strong response, typically within 14 days after the second dose. Neuromuscular diseases are characterized by the progressive loss of muscle and are often treated with chronic glucocorticoid steroids, both of which may contribute to a blunted immune response to vaccination. Here, we measured IgG antibody content and neutralizing antibody response after mRNA COVID-19 vaccination in non-ambulatory neuromuscular disease patients. After two doses of mRNA COVID-19 vaccine, median anti-receptor binding domain IgG and percent surrogate viral neutralization in non-ambulatory neuromuscular disease samples were significantly elevated similar to healthy vaccinated controls. As in healthy controls, COVID-19 vaccines produce greater antibody levels compared to those with a history of outpatient COVID-19 infection. This data documents that non-ambulatory neuromuscular disease patients respond well to two doses of mRNA COVID-19 vaccine despite low muscle mass and even chronic steroid use.

Original languageEnglish (US)
Pages (from-to)33-35
Number of pages3
JournalNeuromuscular Disorders
Volume32
Issue number1
DOIs
StatePublished - Jan 2022

Funding

Supported by the National Science Foundation 2035114, NIH 3UL1TR001422–06S4, Northwestern University Office of Research, and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report. Supported by the National Science Foundation 2035114, NIH 3UL1TR001422?06S4, Northwestern University Office of Research, and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.

Keywords

  • COVID-19
  • Dried blood spots
  • ELISA
  • IgG
  • Muscular dystrophy
  • Neuromuscular
  • Receptor binding domain
  • SARS-CoV-2
  • Serological testing

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Genetics(clinical)
  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease'. Together they form a unique fingerprint.

Cite this